Sagimet Biosciences Inc. (SGMT)
NASDAQ: SGMT · Real-Time Price · USD
7.90
-0.77 (-8.88%)
Aug 15, 2025, 9:55 AM - Market open
Sagimet Biosciences Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 |
| Cash & Equivalents | 42.33 | 75.84 | 75.14 | 0.16 | 56.73 | 68.7 | Upgrade
|
| Short-Term Investments | 83.08 | 75.41 | 19.76 | 32.19 | - | - | Upgrade
|
| Cash & Short-Term Investments | 125.41 | 151.25 | 94.9 | 32.35 | 56.73 | 68.7 | Upgrade
|
| Cash Growth | -24.62% | 59.38% | 193.39% | -42.98% | -17.42% | 572.76% | Upgrade
|
| Prepaid Expenses | 1 | 1.06 | 1.35 | 0.41 | 0.42 | - | Upgrade
|
| Other Current Assets | 0.79 | 0.46 | 0.4 | 0.03 | 1.51 | 0.04 | Upgrade
|
| Total Current Assets | 127.2 | 152.77 | 96.65 | 32.79 | 58.66 | 68.74 | Upgrade
|
| Property, Plant & Equipment | 0.15 | 0.08 | 0.07 | 0.21 | 0.34 | 0.19 | Upgrade
|
| Long-Term Investments | 10.06 | 7.41 | - | - | - | - | Upgrade
|
| Other Long-Term Assets | - | - | - | 0.03 | 0.03 | 0.03 | Upgrade
|
| Total Assets | 137.41 | 160.26 | 96.72 | 33.03 | 59.03 | 68.96 | Upgrade
|
| Accounts Payable | 1.92 | 1.43 | 0.19 | 1.13 | 0.76 | 0.51 | Upgrade
|
| Accrued Expenses | 5.17 | 2.95 | 4.85 | 3.96 | 1.32 | 1.01 | Upgrade
|
| Current Portion of Leases | 0.15 | 0.08 | 0.07 | 0.13 | 0.12 | 0.15 | Upgrade
|
| Other Current Liabilities | 0 | 0.01 | 0.56 | 0.06 | 0.24 | 0.24 | Upgrade
|
| Total Current Liabilities | 7.25 | 4.45 | 5.65 | 5.28 | 2.44 | 1.91 | Upgrade
|
| Long-Term Leases | - | - | - | 0.08 | 0.22 | 0.07 | Upgrade
|
| Other Long-Term Liabilities | - | - | - | 0 | - | - | Upgrade
|
| Total Liabilities | 7.25 | 4.45 | 5.65 | 5.36 | 2.66 | 1.98 | Upgrade
|
| Common Stock | 0 | 0 | 0 | 0 | 0 | 0 | Upgrade
|
| Additional Paid-In Capital | 453.95 | 450.88 | 340.78 | 35 | 33.11 | 31.02 | Upgrade
|
| Retained Earnings | -323.87 | -295.31 | -249.74 | -221.87 | -191.37 | -166.93 | Upgrade
|
| Comprehensive Income & Other | 0.08 | 0.23 | 0.03 | -0.08 | - | - | Upgrade
|
| Total Common Equity | 130.16 | 155.81 | 91.07 | -186.95 | -158.26 | -135.91 | Upgrade
|
| Shareholders' Equity | 130.16 | 155.81 | 91.07 | 27.67 | 56.37 | 66.98 | Upgrade
|
| Total Liabilities & Equity | 137.41 | 160.26 | 96.72 | 33.03 | 59.03 | 68.96 | Upgrade
|
| Total Debt | 0.15 | 0.08 | 0.07 | 0.21 | 0.35 | 0.21 | Upgrade
|
| Net Cash (Debt) | 135.31 | 158.58 | 94.83 | 32.13 | 56.38 | 68.49 | Upgrade
|
| Net Cash Growth | -28.15% | 67.22% | 195.11% | -43.01% | -17.68% | 593.87% | Upgrade
|
| Net Cash Per Share | 4.20 | 5.06 | 9.07 | 174.06 | 459.97 | 709.34 | Upgrade
|
| Filing Date Shares Outstanding | 32.52 | 32.2 | 31.91 | 22.9 | 0.12 | 0.1 | Upgrade
|
| Total Common Shares Outstanding | 32.2 | 32.2 | 22.9 | 0.19 | 0.12 | 0.1 | Upgrade
|
| Working Capital | 119.95 | 148.32 | 90.99 | 27.51 | 56.22 | 66.83 | Upgrade
|
| Book Value Per Share | 4.04 | 4.84 | 3.98 | -1010.08 | -1291.08 | -1407.55 | Upgrade
|
| Tangible Book Value | 130.16 | 155.81 | 91.07 | -186.95 | -158.26 | -135.91 | Upgrade
|
| Tangible Book Value Per Share | 4.04 | 4.84 | 3.98 | -1010.08 | -1291.08 | -1407.55 | Upgrade
|
Updated Aug 13, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.